356 related articles for article (PubMed ID: 23787721)
1. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
Lesogor A; Cohn JN; Latini R; Tognoni G; Krum H; Massie B; Zalewski A; Kandra A; Hua TA; Gimpelewicz C
Eur J Heart Fail; 2013 Nov; 15(11):1236-44. PubMed ID: 23787721
[TBL] [Abstract][Full Text] [Related]
2. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
3. Effect of Valsartan on hospitalization: results from Val-HeFT.
Carson P; Tognoni G; Cohn JN
J Card Fail; 2003 Jun; 9(3):164-71. PubMed ID: 12815565
[TBL] [Abstract][Full Text] [Related]
4. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN
Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728
[TBL] [Abstract][Full Text] [Related]
5. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
7. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
[TBL] [Abstract][Full Text] [Related]
8. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
Bakris GL; Siomos M; Richardson D; Janssen I; Bolton WK; Hebert L; Agarwal R; Catanzaro D
Kidney Int; 2000 Nov; 58(5):2084-92. PubMed ID: 11044229
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Cohn JN; Tognoni G;
N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
[TBL] [Abstract][Full Text] [Related]
10. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
Baruch L; Glazer RD; Aknay N; Vanhaecke J; Heywood JT; Anand I; Krum H; Hester A; Cohn JN
Am Heart J; 2004 Dec; 148(6):951-7. PubMed ID: 15632877
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
12. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
Maggioni AP; Anand I; Gottlieb SO; Latini R; Tognoni G; Cohn JN;
J Am Coll Cardiol; 2002 Oct; 40(8):1414-21. PubMed ID: 12392830
[TBL] [Abstract][Full Text] [Related]
13. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study).
Vardeny O; Wu DH; Desai A; Rossignol P; Zannad F; Pitt B; Solomon SD;
J Am Coll Cardiol; 2012 Nov; 60(20):2082-9. PubMed ID: 23083787
[TBL] [Abstract][Full Text] [Related]
14. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
Krum H; Carson P; Farsang C; Maggioni AP; Glazer RD; Aknay N; Chiang YT; Cohn JN
Eur J Heart Fail; 2004 Dec; 6(7):937-45. PubMed ID: 15556056
[TBL] [Abstract][Full Text] [Related]
15. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Latini R; Masson S; Anand I; Judd D; Maggioni AP; Chiang YT; Bevilacqua M; Salio M; Cardano P; Dunselman PH; Holwerda NJ; Tognoni G; Cohn JN;
Circulation; 2002 Nov; 106(19):2454-8. PubMed ID: 12417542
[TBL] [Abstract][Full Text] [Related]
16. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT).
Butler J; Anand IS; Kuskowski MA; Rector T; Carson P; Cohn JN;
Congest Heart Fail; 2010; 16(5):191-5. PubMed ID: 20887614
[TBL] [Abstract][Full Text] [Related]
17. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
Cohn JN; Anand IS; Latini R; Masson S; Chiang YT; Glazer R;
Circulation; 2003 Sep; 108(11):1306-9. PubMed ID: 12939207
[TBL] [Abstract][Full Text] [Related]
18. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Pradelli L; Iannazzo S; Zaniolo O
Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
[TBL] [Abstract][Full Text] [Related]
19. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN
Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459
[TBL] [Abstract][Full Text] [Related]
20. The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.
Tan LB; Schlosshan D; Williams SG
Int J Clin Pract; 2004 Feb; 58(2):184-91. PubMed ID: 15055867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
